NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

You’re ignoring that this has been the long term plan all along, and you are lying that it can’t be done the way it was planned. Instead:

In pharmaceutical manufacturing, a company can initially gain approval based on a clinically-used process, then submit a Type II Variation (a major change) to switch to a more efficient, scaled-up process once it is ready and validated. This variation requires submission of new data to demonstrate that the product made by the new (Flaskworks/Grade C) process is equivalent in quality, safety, and efficacy to the product made by the clinical (Artisan/Grade B) process.